Leaders from across the healthcare sector met yesterday to discuss the importance of bolstering the antibiotic pipeline to keep up with the threat of #superbugs. Watch their recommendations for staying ahead of #AMR.
https://t.co/zHkGefQZ0J
As antimicrobial resistance (#AMR) continues to spread and become deadlier, the need for new drugs has never been clearer. We're glad to be part of today’s discussion at #MIGlobal https://t.co/jZ77VJELU6 #biotech
We’re excited to be participating in the Milken Institute Global Conference! Tune in tomorrow to hear Forge CSO Andrew Tomaras discuss how we’re working to combat #AMR through innovation. https://t.co/jZ77VJELU6 #MIGlobal
Read my latest in @sdut with @ForgeThera Chief Scientific Officer Dr. Andrew Tomaras about #AntimicrobialResistance – and the importance of shaping policy that supports research, development and production of new #antibiotics https://t.co/FDMR1FUGEz
We’re pleased to announce the appointment of Peter Warn, Ph.D., to the Forge Therapeutics Antibiotic Advisory Board! An experienced antimicrobial discovery scientist, Dr. Warn brings to Forge a long and successful record of working in the anti-infective discovery industry.
Please join us in congratulating John Rex on his new position as the SAB chair of the AMR Action Fund! Dr. Rex has dedicated years of service to Forge, helping shape our strategy of developing truly novel antibiotics. #leadership#AMR
We're happy to announce @JohnRex_NewAbx’s appointment as Chair of our Scientific Advisory Board. Dr. Rex brings over 30 years of drug development and policy experience focused on antimicrobial agents. https://t.co/wcIQVgjUUE #AMR#AntimicrobialResistance
We are pleased to announce the appointment of Dr. Andrew Tomaras as Chief Scientific Officer! Dr. Tomaras will be responsible for advancing Forge’s pipeline of novel antibiotics into the clinic along with directing other anti-infective efforts. https://t.co/MnqeHsWj3I #leadership
We're excited to welcome Lloyd Payne, Ph.D., one of the world's leading antibiotic KOLs, to our Antibiotic Advisory Board! Dr. Payne is Founding CEO of specialty anti-infective CRO Euprotec, EVP & Head of Anti-Infectives at Evotec and on NOVO Repair’s Scientific Selection Board.
Congrats to our scientific co-founder Seth Cohen, Ph.D. for making such a prestigious list!
52 UC San Diego Researchers Are Named Highly Cited in 2020 Listing https://t.co/ypQGpXfGfi
During COVID, the growing dangers and threat posed by antibiotic-resistant bacteria outweigh the global level of preparedness. Meanwhile, antibiotic R&D is suffering for investment. Forge applauds @Merck and Kyorin for supporting @PewCharitableTrust https://t.co/i0ToNjccgt
Check it out! Today and tomorrow, we will be discussing the future of antibiotic development alongside @CARB_X and @Roche at this month’s World Antimicrobial Resistance Congress 2020. https://t.co/Yf6aEw2hC6 #antibiotics#drugdiscovery#AMR#StopAMR
Antimicrobial resistance #AMR is building into a new #pandemic. One way to fight it? The DISARM Act. Contact Congress and help pass this lifesaving legislation by clicking here: https://t.co/BYoB3icVOy
Society desperately needs new antibiotics but, right now, there is no viable market for them. We’re joining others in backing a new $1 billion @AMRActionFund that aims to bring 2 to 4 new antibiotics to patients by 2030.
Press release: https://t.co/Pi30uZY3He
*GREAT NEWS* -- The pharma industry is launching a $1-billion @AMRActionFund to develop antibiotics. The goal is to deliver 2-4 new drugs by the end of the decade to save modern medicine from deadly drug-resistant infections.
https://t.co/Wi6zrgv76O